Atea Pharmaceuticals, Inc. Investing Cash Flow
Atea Pharmaceuticals, Inc. (AVIR) reported Investing Cash Flow of $64.05 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Cash Flow › Investing Activities
us-gaap:NetCashProvidedByUsedInInvestingActivities · last filed 2026-08-12
- Atea Pharmaceuticals, Inc. net cash provided by (used in) investing activities for the quarter ending 2026-06-30 was $34.31M, a 124.43% increase year-over-year.
- Atea Pharmaceuticals, Inc. net cash provided by (used in) investing activities for the quarter ending 2026-03-31 was $29.74M, a 65.26% decline year-over-year.
- Atea Pharmaceuticals, Inc. net cash provided by (used in) investing activities for the quarter ending 2025-12-31 was $46.59M.
- Atea Pharmaceuticals, Inc. net cash provided by (used in) investing activities for the quarter ending 2025-09-30 was $41.30M.
- Atea Pharmaceuticals, Inc. net cash provided by (used in) investing activities for fiscal 2025 was $188.79M, a 236.50% increase from fiscal 2024.
- Atea Pharmaceuticals, Inc. net cash provided by (used in) investing activities for fiscal 2024 was $56.10M, a 39.21% increase from fiscal 2023.
- Atea Pharmaceuticals, Inc. net cash provided by (used in) investing activities for fiscal 2023 was $40.30M.
- Atea Pharmaceuticals, Inc. net cash provided by (used in) investing activities for fiscal 2022 was -$455.41M.
| Period end | Net Cash Provided by (Used in) Investing Activities 3 month | Net Cash Provided by (Used in) Investing Activities 6 month | Net Cash Provided by (Used in) Investing Activities 9 month | Net Cash Provided by (Used in) Investing Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $34.31M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | $64.05M 10-Q · filed 2026-08-12 | $110.64M derived: sum of 3 quarters · filed 2026-08-12 | $151.95M derived: sum of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | $29.74M 10-Q · filed 2026-05-12 | $76.33M derived: sum of 2 quarters · filed 2026-05-12 | $117.63M derived: sum of 3 quarters · filed 2026-05-12 | $132.92M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-12-31 | $46.59M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $87.89M derived: sum of 2 quarters · filed 2026-03-05 | $103.19M derived: sum of 3 quarters · filed 2026-08-12 | $188.79M 10-K · filed 2026-03-05 |
| 2025-09-30 | $41.30M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $56.59M derived: sum of 2 quarters · filed 2026-08-12 | $142.20M 10-Q · filed 2025-11-12 | $138.83M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-06-30 | $15.29M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | $100.90M 10-Q · filed 2026-08-12 | $97.53M derived: sum of 3 quarters · filed 2026-08-12 | -$24.48M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-03-31 | $85.61M 10-Q · filed 2026-05-12 | $82.24M derived: sum of 2 quarters · filed 2026-05-12 | -$39.77M derived: sum of 3 quarters · filed 2026-05-12 | $84.91M derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | -$3.37M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | -$125.38M derived: sum of 2 quarters · filed 2026-03-05 | -$697.00K derived: sum of 3 quarters · filed 2026-03-05 | $56.10M 10-K · filed 2026-03-05 |
| 2024-09-30 | -$122.01M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $2.67M derived: sum of 2 quarters · filed 2025-11-12 | $59.48M 10-Q · filed 2025-11-12 | $87.25M derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | $124.69M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $181.49M 10-Q · filed 2025-08-07 | $209.26M derived: sum of 3 quarters · filed 2025-08-07 | $150.75M derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | $56.80M 10-Q · filed 2025-05-12 | $84.57M derived: sum of 2 quarters · filed 2025-05-12 | $26.06M derived: sum of 3 quarters · filed 2025-05-12 | $72.63M derived: sum of 4 quarters · filed 2025-05-12 |
| 2023-12-31 | $27.77M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-06 | -$30.74M derived: sum of 2 quarters · filed 2025-03-06 | $15.82M derived: sum of 3 quarters · filed 2025-03-06 | $40.30M 10-K · filed 2025-03-06 |
| 2023-09-30 | -$58.51M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | -$11.95M derived: sum of 2 quarters · filed 2024-11-07 | $12.53M 10-Q · filed 2024-11-07 | $46.02M derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-06-30 | $46.56M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-07 | $71.05M 10-Q · filed 2024-08-07 | $104.53M derived: sum of 3 quarters · filed 2024-08-07 | -$382.44M derived: sum of 4 quarters · filed 2024-08-07 |
| 2023-03-31 | $24.48M 10-Q · filed 2024-05-14 | $57.97M derived: sum of 2 quarters · filed 2024-05-14 | -$429.01M derived: sum of 3 quarters · filed 2024-05-14 | -$430.89M derived: sum of 4 quarters · filed 2024-05-14 |
| 2022-12-31 | $33.49M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | -$453.49M derived: sum of 2 quarters · filed 2024-02-28 | -$455.37M derived: sum of 3 quarters · filed 2024-02-28 | -$455.41M 10-K · filed 2024-02-28 |
| 2022-09-30 | -$486.98M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | -$488.85M derived: sum of 2 quarters · filed 2023-11-08 | -$488.90M 10-Q · filed 2023-11-08 | |
| 2022-06-30 | -$1.88M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | -$1.92M 10-Q · filed 2023-08-08 | ||
| 2022-03-31 | -$44.00K 10-Q · filed 2023-05-08 | |||
| 2021-12-31 | -$4.00K 10-K · filed 2023-02-28 | |||
| 2020-12-31 | -$5.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | -$20.00K derived: sum of 2 quarters · filed 2023-02-28 | -$26.00K 10-K · filed 2023-02-28 | |
| 2020-09-30 | -$15.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-12 | -$21.00K 10-Q · filed 2021-11-12 | ||
| 2020-06-30 | -$6.00K 10-Q · filed 2021-08-12 | |||
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | -$2.00K 10-K · filed 2022-02-28 | ||
| 2019-09-30 | -$2.00K 10-Q · filed 2020-12-10 | |||
| 2018-12-31 | -$12.00K 10-K · filed 2021-03-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 |